Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · IEX Real-Time Price · USD
0.670
-0.010 (-1.43%)
At close:
Feb 7, 2023, 3:59 PM
0.690
+0.020 (2.97%)
After-hours:
Feb 7, 2023, 5:48 PM EST
Income Statement (Annual)
Financials in millions USD. Fiscal year is May - April.
Millions USD. Fiscal year is May - Apr.
Year | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|
Selling, General & Admin
|
7.12 | 3.64 | 3.35 | 1.31 |
Research & Development
|
5.2 | 1.31 | 1.07 | 3.7 |
Operating Expenses
|
12.32 | 4.95 | 4.42 | 5.01 |
Operating Income
|
-12.32 | -4.95 | -4.42 | -5.01 |
Interest Expense / Income
|
0.05 | 0.16 | 0 | 0 |
Other Expense / Income
|
-0 | -0.06 | -0.01 | -0.15 |
Pretax Income
|
-12.36 | -5.05 | -4.41 | -4.86 |
Net Income
|
-12.36 | -5.05 | -4.41 | -4.86 |
Shares Outstanding (Basic)
|
89 | 73 | 71 | 59 |
Shares Outstanding (Diluted)
|
89 | 73 | 71 | 59 |
Shares Change
|
22.64% | 1.96% | 21.09% | - |
EPS (Basic)
|
-0.14 | -0.07 | -0.06 | -0.08 |
EPS (Diluted)
|
-0.14 | -0.07 | -0.06 | -0.08 |
Free Cash Flow Per Share
|
-0.07 | -0.04 | -0.03 | -0.02 |
EBITDA
|
-12.31 | -4.89 | -4.41 | -4.86 |
Depreciation & Amortization
|
0 | 0 | 0 | 0 |
EBIT
|
-12.32 | -4.89 | -4.41 | -4.86 |
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).